TRAIL bağlı altın nanoparçacıkların glioblastoma TRAIL direncindeki etkisinin incelenmesi

Glioblastomalar, cerrahi tedavideki gelişmelere rağmen, kemoterapiye ve radyoterapiye direnç gösterdikleri için alternatif tedavi yaklaşımlarına büyük ihtiyaç duyulmaktadır. Glioblastomalarda hayatta kalma ve apoptoz mekanizması aynı madalyonun iki farklı yüzü olarak görüldüğünde, mevcut tedavi stratejilerinin doğru tümör hücre popülasyonlarını hedef alıp almadığı sorusu gündeme gelmektedir. TRAIL, sadece tümör hücrelerinde apoptozu indükleyen en iyi ajanlardan biridir ancak tümör hücreleri TRAIL'e farklı duyarlılık göstermektedir. Bu çalışmada, TRAIL, altın nanoparcaçıklar yüzeyinde aktive edilip, TRAIL'e duyarlı ve dirençli glioblastoma hücrelerde canlılığı, ve kaspaz aktivitesini nasıl etkilediği araştırılmıştır. Bu çalışmanın sonuçları, gelecekte glioblastoma icin etkili tedavilerin tasarımında faydalı olacaktır.

Anahtar Kelimeler:

İlac direnci, Altın nanoparçacık, Hücre canlılığı, Glioblastoma, TRAIL

PDF

___

[1] Malignant astrocytic glioma: genetics, biology, and paths to treatment.
[2] An integrated genomic analysis of human glioblastoma multiforme.
[3] Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial.
[4] The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
[5]Apo2L/TRAIL and its death and decoy receptors.
[6] TRAIL in cancer therapy: present and future challenges.
[7] Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
[8] Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
[9] Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
[10] argeting death receptors in cancer with Apo2L/TRAIL.
[11] Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.
[12] Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
[13] Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. [14] TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.
[15] Interaction of multi-functional silver nanoparticles with living cells.
[16] The influence of the surface chemistry of silver nanoparticles on cell death
[17] In colloidal gold: principles, methods, and. applications.
[18] Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
[19] TRAIL-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages.
[20]Gold Nanoparticles Enhance TRAIL Sensitivity Through Drp1-Mediated Apoptotic and Autophagic Mitochondrial Fission in NSCLC Cells.